# EGFR-TKI With Chemotherapy in NSCLC Patients With Both EGFR Mutation and BIM Deletion Polymorphism

> **NCT02859077** · PHASE3 · UNKNOWN · sponsor: **Shanghai Pulmonary Hospital, Shanghai, China** · enrollment: 100 (estimated)

## Conditions studied

- Non-Small-Cell Lung Cancer

## Interventions

- **DRUG:** EGFR-TKI
- **DRUG:** Chemotherapy（pemetrexed/gemcitabine）
- **DRUG:** Chemotherapy（carboplatin）

## Key facts

- **NCT ID:** NCT02859077
- **Lead sponsor:** Shanghai Pulmonary Hospital, Shanghai, China
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2016-08
- **Primary completion:** 2017-07
- **Final completion:** 2018-07
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2016-08-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02859077

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02859077, "EGFR-TKI With Chemotherapy in NSCLC Patients With Both EGFR Mutation and BIM Deletion Polymorphism". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02859077. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*